Compare American Tower Corp (AMT) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Tower Corp vs ResMed Inc. — how do they compare? American Tower Corp trades at $171.34 (market cap $79.00B), while ResMed Inc. trades at $225.22 (market cap $32.61B). The key difference: American Tower Corp is far larger — about 2.4× ResMed Inc.'s market cap, and American Tower Corp pays the higher dividend (4.12%). Which is the better fit depends on your goals.
| AMT | RMD | |
|---|---|---|
Market Cap | $79.00B | $32.61B |
Sector | Real Estate | Health |
52-Week High | $211.88 | $293.73 |
52-Week Low | $162.11 | $182.82 |
Enterprise Value | $122.53B | $31.97B |
Dividend Yield | 4.12% | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
American Tower (AMT) trades at $169.11, down 1.99% on the day, with technical indicators showing bearish momentum despite strong fundamental performance. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of $1.86 exceeding the $1.57 estimate. Revenue trends show steady growth from $10.1B in 2024 to $10.6B in 2025, with net income margins improving to 23.76%. Recent news highlights strong Q2 2026 results and institutional buying activity.
Wall Street maintains strong bullish sentiment with 39 buy ratings and a $206.17 price target representing 22% upside potential. Key risks include interest rate sensitivity and DISH Network churn impacts. The stock offers defensive characteristics with resilient telecom demand and 5G/6G growth catalysts, though high debt levels and bearish technical signals warrant caution near-term.
ResMed (RMD) trades at $221.22, up 0.53% with a bullish technical signal and strong fundamental performance. The company delivered four consecutive quarterly earnings beats, with Q4 2026 EPS of $2.95 beating expectations by 2.1%. Revenue grew 9% year-over-year to $1.5 billion, while maintaining robust profitability with 61.1% gross margins and 26.9% net income margins. Recent strategic moves include the $490 million sale of MatrixCare to focus on core sleep and respiratory care markets.
The stock presents a compelling growth story with consistent execution, though near-term headwinds from weak 2027 revenue guidance create uncertainty. Analyst consensus targets $235.00 (6.2% upside) with 40% buy ratings. Key risks include ventilator sales suspension, cost pressures, and competitive threats in the medical device space. The company's strong cash flow generation and shareholder returns ($1.0 billion in 2026) support long-term value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Tower Corp
American Tower owns and operates more than 220,000 cell towers throughout the U.S., Asia, Latin America, Europe, and Africa. It also owns and/or operates 25 data centers in eight U.S. markets after acquiring CoreSite. On its towers, the company has a very concentrated customer base, with most revenue in each market being generated by just the top few mobile carriers. The company operates more than 40,000 towers in the U.S., which accounted for more than half of its total revenue in 2021. Outside the U.S., American Tower's greatest presence is in India and Brazil, where it operates roughly 75,000 and 19,000 towers, respectively. American Tower operates as a real estate investment trust.
Read more on AMT →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
